The 52-week high and low prices can offer valuable insights into a stock’s current standing and prospects for future performance. Summit Therapeutics Inc’s current trading price is -44.89% away from its 52-week high, while its distance from the 52-week low is 1038.73%. The stock’s price range for this period has been between $1.64 and $33.89 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 6.55 million for the day, a number notably higher than the average daily volume of 4.85 million over the last three months.
Summit Therapeutics Inc experienced a somewhat steady performance in the stock market. The company’s stock reached a 1-year high of $33.89 on 09/16/24, while the lowest price for the same period was registered at $1.64 on 11/09/23.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
Summit Therapeutics Inc (SMMT) has experienced a quarterly rise of 147.35% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 13.53B and boasts a workforce of 105 employees.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 11.88, with a change in price of +14.31. Similarly, Summit Therapeutics Inc recorded 5,184,268 in trading volume during the last 100 days, posting a change of +298.23%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for SMMT stands at 0.56. Similarly, the long-term debt-to-equity ratio is also 0.03.
SMMT Stock Stochastic Average
Summit Therapeutics Inc’s raw stochastic average for the past 50 days is presently 40.92%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 17.63%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 27.79% and 33.94%, respectively.
SMMT Stock Price Performance Analysis
The stock price performance over the year has been a mixed bag, resulting in a range of outlooks from optimistic to pessimistic depending on the observer. The index has shown a price gain of 615.52% this year. Over the last six months, there has been a weaker performance of 381.32%. The price of SMMT fallen by 49.40% during the last 30 days period. For the last 5-days stocks have slided -10.58%.
